cyclophosphamide

P1/2, N=120, Recruiting, Beijing Mabworks Biotech Co., Ltd. | Trial primary completion date: Nov 2024 --> Mar 2025

P1, N=18, Recruiting, The First Affiliated Hospital of Soochow University

P2, N=72, Completed, Ain Shams University | Recruiting --> Completed

P3, N=174, Active, not recruiting, The Netherlands Cancer Institute | Trial primary completion date: Oct 2024 --> Jul 2025

P1, N=10, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd.

Combined paclitaxel/CKM regimen was safe, with desirable TME changes and preliminary indications of promising pCR+ypTmic of 66%, comparable to the combination of NAC with pembrolizumab.

P2, N=46, Recruiting, European Institute of Oncology | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Jul 2023 --> Dec 2024

P1, N=21, Active, not recruiting, University of Florida | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

P2, N=75, Recruiting, Institute of Hematology & Blood Diseases Hospital, China

P2, N=262, Completed, Children's Oncology Group | Active, not recruiting --> Completed

P2, N=35, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 35 | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Mar 2025

Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab (R-CHOP) resulted in complete molecular remission (CMR). The antibody test for JCV is recommended for patients with multiple sclerosis for an earlier diagnosis, which is not common in other diseases. We should be aware of PML through innovative therapy.

Findings verify for the first time the neuroprotective potential of golden berry leaf, currently discarded as agricultural waste, and highlight its multifaceted mechanism of neuroprotection in CP-induced neurotoxicity, suggesting its suitability as a promising therapeutic agent for neurotoxicity management.

P3, N=20, Recruiting, Amgen | Not yet recruiting --> Recruiting

P2, N=44, Recruiting, Zhejiang Cancer Hospital | Not yet recruiting --> Recruiting

P=N/A, N=380, Recruiting, Peking University People's Hospital

P2, N=6, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025

This is the first prospective trial to evaluate adjuvant GVAX, Cy, SBRT, and mFFX in resected PDAC patients with high-risk features. This combination regimen was well tolerated with limited toxicity and promising survival outcomes, warranting future studies to validate this regimen in the adjuvant setting.

Venetoclax was given for 21 days with each cycle of mini-hyper-CVD (cyclophosphamide, vincristine, dexamethasone alternating with methotrexate and cytarabine). In summary, for patients with newly diagnosed ALL, venetoclax plus mini-HCVD is well-tolerated with promising efficacy. NCT03319901.

Our study demonstrates that our local population has similar clinicopathological and prognostic characteristics of DLBCL as compared to global findings. It also highlights the limitations of R-CHOP(-like) regimens in contemporary DLBCL management and therefore an ongoing need for improved therapeutic strategies.

The patient was treated with six cycles of the R-CHOP regimen (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone), achieving complete metabolic remission as confirmed by positron emission tomography-computed tomography. Through our literature review of additional six cases of primary seminal vesicle lymphoma, we aim to elucidate the typical clinical presentations, imaging features, pathological characteristics, genetic mutations, and therapeutic strategies, aiming to contribute to better detection and management of this rare malignancy. This case underscores the diagnostic challenges and emphasizes the necessity for heightened clinical suspicion and definitive pathological examination in the management of primary seminal vesicle lymphoma.

Considered as a whole, the aqueous leaf extract of Brillantaisia patula reversed oxidative stress and inflammatory side effects of cyclophosphamide, preserving ovarian function and fertility in the rats. This may suggest its exploration as a safe agent against toxic side effects of chemotherapy and fertility-related disorders of the uterus and ovary.

The patient underwent a multimodal treatment approach, including bladder-preserving surgery, 12 cycles of high-dose MRTK-2020 neoadjuvant chemotherapy [comprising actinomycin D, vincristine, doxorubicin, cyclophosphamide (AVDC), ifosfamide, carboplatin, and etoposide (ICE)], followed by adjuvant radiotherapy. Despite the limited evidence base, bladder-preserving surgeries, when feasible, should be considered and accompanied by adjuvant therapies for optimal outcomes. This case illustrates the potential for successful treatment of pure MRTs of the bladder using a combination of surgery, chemotherapy, and radiotherapy.

Furthermore, 48 women with luminal/HER2-low (IHC 2+/FISH-negative) high-risk EBC are enrolled to receive neoadjuvant pyrotinib plus chemotherapy (epirubicin-cyclophosphamide followed by docetaxel). In conclusion, neoadjuvant pyrotinib plus chemotherapy has encouraging efficacy and manageable toxicity in women with luminal/HER2-low (IHC 2+/FISH-negative) high-risk EBC. This regimen warrants to be further validated.

Low‒dose Cy enhances tumoricidal effects of 5‒day spacing high‒dose RT by increasing anti-tumor immune responses.

He was administered alemtuzumab twice (at the time of initial treatment and relapse) and cyclophosphamide, vincristine, and hydrocortisone chemotherapy. Furthermore, novel therapeutic drugs (venetoclax and tofacitinib) were administered based on previous case reports...Consideration should be given to suspending treatment, adjusting the administration interval, or administering G-CSF if necessary. The treatment interval can be appropriately adjusted, making it a valuable treatment option for refractory T-PLL.

P=N/A, N=50, Completed, University of Auckland | Recruiting --> Completed

P2, N=37, Recruiting, David Bond, MD | Trial primary completion date: Dec 2024 --> Dec 2025

P2, N=30, Recruiting, First Affiliated Hospital of Zhejiang University | N=50 --> 30 | Trial completion date: Oct 2029 --> Jun 2029 | Initiation date: Oct 2024 --> Jun 2024 | Trial primary completion date: Oct 2026 --> Jun 2026

P2, N=45, Not yet recruiting, European Institute of Oncology

P1, N=20, Recruiting, Nova Therapeutics LLC | Trial primary completion date: Dec 2024 --> Dec 2025

The CHOP regimen induces male reproductive toxicity, potentially mediated through alterations in hormone levels and increased expression of inflammatory cytokines and oxidative stress. Using E2 as the sole predictor in the model accurately predicts the extent of reproductive damage, offering a non-invasive method for detecting reproductive system damage.

P1, N=19, Terminated, Beijing Boren Hospital | Recruiting --> Terminated; ethic commitee decision

P1, N=0, Withdrawn, Beijing Boren Hospital | Trial completion date: Dec 2025 --> Dec 2023 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Dec 2023

P1, N=0, Withdrawn, Beijing Boren Hospital | N=18 --> 0 | Trial completion date: Jul 2024 --> Dec 2023 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2024 --> Dec 2023

P1, N=16, Completed, Beijing Boren Hospital | Recruiting --> Completed

P1/2, N=18, Not yet recruiting, Beijing GoBroad Hospital

P3, N=5949, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Oct 2025

P3, N=847, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025

P2, N=50, Recruiting, Emory University | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2025 --> Nov 2026

P2, N=83, Active, not recruiting, Memorial Sloan Kettering Cancer Center

P1, N=35, Recruiting, Sana Biotechnology | Initiation date: Oct 2024 --> Apr 2024